<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051605</url>
  </required_header>
  <id_info>
    <org_study_id>RHDIRB2020110301 REC 45</org_study_id>
    <nct_id>NCT05051605</nct_id>
  </id_info>
  <brief_title>Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation</brief_title>
  <official_title>Evaluation of the Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective cohort study to evaluate the response to COVID-19 vaccine in liver&#xD;
      transplantation patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      fifty living donor liver transplantation recipients during maintenance immunosuppression&#xD;
      phase will be vaccinated against COVID-19 followed by assessment of immune response to the&#xD;
      vaccine and further investigation of correlation of immune response to genetic polymorphisms&#xD;
      of HLA DRB1(rs2647087) gene and IL-18 (rs187238 and rs917997) gene.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralizing antibody titer change 14 days after vaccination compared to baseline</measure>
    <time_frame>At baseline, at 14 days after whole course of vaccination</time_frame>
    <description>neutralizing antibody response to SARS-CoV-2 vaccine in recipients post living donor liver transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody titer change 28 days post vaccination compared to baseline</measure>
    <time_frame>At baseline and 28 days after whole course of vaccination</time_frame>
    <description>neutralizing antibody response to SARS-CoV-2 vaccine in recipients post living donor liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 serum level</measure>
    <time_frame>At baseline, at 14 and 28 days after whole course of vaccination</time_frame>
    <description>Assessing the cellular immunological response to SARS-CoV-2 vaccine in recipients post living donor liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of confirmed coronavirus disease</measure>
    <time_frame>28 days after whole course of vaccination</time_frame>
    <description>Patient follow-up for confirmed symptomatic infection by SARS-COV2 virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to vaccine</measure>
    <time_frame>7 days after each dose of the vaccine and up to 28 days after last vaccine dose administered</time_frame>
    <description>Self reported safety and tolerability of vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft rejection</measure>
    <time_frame>On 14 and 28 days post whole course vaccination</time_frame>
    <description>Follow-up for signs and symptoms of graft rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response correlation to HLA DRB1 genetic polymorphism</measure>
    <time_frame>28 days post whole course vaccination</time_frame>
    <description>TaqMan®️ SNP genotyping assay of HLA DRB1 gene (rs2647087)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response correlation to IL-18 genetic polymorphism</measure>
    <time_frame>28 days post whole course vaccination</time_frame>
    <description>TaqMan®️ SNP genotyping assay of IL-18 gene (rs187238 and rs917997)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>Vaccinated group</arm_group_label>
    <description>Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>Severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2)vaccine according to vaccine availability in the Egyptian ministry of health.</description>
    <arm_group_label>Vaccinated group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Living donor liver transplantation recipients willing to be vaccinated against COVID-19 and&#xD;
        capable of signing an informed consent to participate in this cohort&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18&#xD;
&#xD;
          -  At least 3 month post transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pediatric recipients&#xD;
&#xD;
          -  Active covid infection at the time of the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Allergy to any ingredients included in the vaccine&#xD;
&#xD;
          -  Lactation in first six month of delivery&#xD;
&#xD;
          -  Active Acute cellular rejection proven by liver biopsy&#xD;
&#xD;
          -  Acute Febrile state with either leucopenia or leucocytosis&#xD;
&#xD;
          -  High dose of corticosteroid at study timing (pulse methyl prednisolone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rana Sayed, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Pharmacy, Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rana Sayed, PhD</last_name>
    <phone>01208164247</phone>
    <phone_ext>+2</phone_ext>
    <email>ranasayed@pharma.asu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Alaa, Msc</last_name>
    <phone>01112119264</phone>
    <phone_ext>+2</phone_ext>
    <email>Sarah_alaaosman52@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams center for organ transplantation (ASCOT), Ain shams university specialized hospital</name>
      <address>
        <city>Cairo</city>
        <state>Please Select Region, State Or Province</state>
        <zip>11765</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rana Sayed, PhD</last_name>
      <phone>01208164247</phone>
      <phone_ext>+2</phone_ext>
      <email>ranasayed@pharma.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Rana Sayed Fouad</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>transplantation</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

